Literature DB >> 9218794

Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release.

F J van Kuppeveld1, J G Hoenderop, R L Smeets, P H Willems, H B Dijkman, J M Galama, W J Melchers.   

Abstract

Digital-imaging microscopy was performed to study the effect of Coxsackie B3 virus infection on the cytosolic free Ca2+ concentration and the Ca2+ content of the endoplasmic reticulum (ER). During the course of infection a gradual increase in the cytosolic free Ca2+ concentration was observed, due to the influx of extracellular Ca2+. The Ca2+ content of the ER decreased in time with kinetics inversely proportional to those of viral protein synthesis. Individual expression of protein 2B was sufficient to induce the influx of extracellular Ca2+ and to release Ca2+ from ER stores. Analysis of mutant 2B proteins showed that both a cationic amphipathic alpha-helix and a second hydrophobic domain in 2B were required for these activities. Consistent with a presumed ability of protein 2B to increase membrane permeability, viruses carrying a mutant 2B protein exhibited a defect in virus release. We propose that 2B gradually enhances membrane permeability, thereby disrupting the intracellular Ca2+ homeostasis and ultimately causing the membrane lesions that allow release of virus progeny.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218794      PMCID: PMC1169977          DOI: 10.1093/emboj/16.12.3519

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  40 in total

1.  Inhibition of DNA-primed RNA synthesis during poliovirus infection of human cells.

Authors:  J J HOLLAND
Journal:  Biochem Biophys Res Commun       Date:  1962-12-19       Impact factor: 3.575

Review 2.  Interactions between membranes and cytolytic peptides.

Authors:  A W Bernheimer; B Rudy
Journal:  Biochim Biophys Acta       Date:  1986-06-12

3.  Coxsackie B3 virus protein 2B contains cationic amphipathic helix that is required for viral RNA replication.

Authors:  F J van Kuppeveld; J M Galama; J Zoll; P J van den Hurk; W J Melchers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Kissing of the two predominant hairpin loops in the coxsackie B virus 3' untranslated region is the essential structural feature of the origin of replication required for negative-strand RNA synthesis.

Authors:  W J Melchers; J G Hoenderop; H J Bruins Slot; C W Pleij; E V Pilipenko; V I Agol; J M Galama
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Structure-function analysis of coxsackie B3 virus protein 2B.

Authors:  F J Van kuppeveld; W J Melchers; K Kirkegaard; J R Doedens
Journal:  Virology       Date:  1997-01-06       Impact factor: 3.616

6.  Incorporation of lipid precursors into cytoplasmic membranes of poliovirus-infected HeLa cells.

Authors:  A G Mosser; L A Caliguiri; I Tamm
Journal:  Virology       Date:  1972-01       Impact factor: 3.616

7.  Poliovirus-induced inhibition of host-cell protein synthesis.

Authors:  E Ehrenfeld
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

8.  Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin.

Authors:  M Nokta; D Eaton; O S Steinsland; T Albrecht
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

9.  Intracellular distribution of poliovirus proteins and the induction of virus-specific cytoplasmic structures.

Authors:  K Bienz; D Egger; Y Rasser; W Bossart
Journal:  Virology       Date:  1983-11       Impact factor: 3.616

10.  Cellular origin and ultrastructure of membranes induced during poliovirus infection.

Authors:  A Schlegel; T H Giddings; M S Ladinsky; K Kirkegaard
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  130 in total

1.  A cysteine-rich motif in poliovirus protein 2C(ATPase) is involved in RNA replication and binds zinc in vitro.

Authors:  T Pfister; K W Jones; E Wimmer
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Deletion mapping of the encephalomyocarditis virus primary cleavage site.

Authors:  H Hahn; A C Palmenberg
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation.

Authors:  A Deora; L Ratner
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Homomultimerization of the coxsackievirus 2B protein in living cells visualized by fluorescence resonance energy transfer microscopy.

Authors:  Frank J M van Kuppeveld; Willem J G Melchers; Peter H G M Willems; Theodorus W J Gadella
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 5.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  Strand-specific RNA synthesis defects in a poliovirus with a mutation in protein 3A.

Authors:  Natalya L Teterina; Mario S Rinaudo; Ellie Ehrenfeld
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Complex dynamic development of poliovirus membranous replication complexes.

Authors:  George A Belov; Vinod Nair; Bryan T Hansen; Forrest H Hoyt; Elizabeth R Fischer; Ellie Ehrenfeld
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 8.  Ion channels as antivirus targets.

Authors:  Xin Liang; Zhi-Yuan Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

Review 9.  T cell epitopes and post-translationally modified epitopes in type 1 diabetes.

Authors:  John W McGinty; Meghan L Marré; Veronique Bajzik; Jon D Piganelli; Eddie A James
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

10.  Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells.

Authors:  Wei Ding; Björn Albrecht; Robert E Kelley; Natarajan Muthusamy; Seung-Jae Kim; Ruth A Altschuld; Michael D Lairmore
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.